BridgeBio Pharma Inc
NASDAQ:BBIO
BridgeBio Pharma Inc
NASDAQ:BBIO
Price:
67.91
USD
-0.34%
Market Cap:
$13.1B
Relative Value
The Relative Value of one
BBIO
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 67.91 USD,
BridgeBio Pharma Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BBIO Relative Value
HIDDEN
Multiples Across Competitors
BBIO Competitors Multiples
BridgeBio Pharma Inc Competitors
BridgeBio Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
13.1B USD | 37.3 | -16.5 | -25.8 | -25.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.9B USD | 6.8 | 172.1 | 16.6 | 23.6 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 377 | -2 377 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
205.8B USD | 5.6 | 26.6 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD | 6.2 | 21.6 | 14.7 | 14.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.6B USD | 10.4 | 31.5 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD | 5.7 | 18.2 | 13.8 | 15.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR | 14.3 | 33.7 | 57.9 | 59.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD | 3.1 | 16.3 | 11.2 | 14 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
